Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,008 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dementias Clear all

Conditions: Aging, Long-Term Care
Interventions: Aim2 - Daily Mouth Care, Aim3 - Daily Mouth Care; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Alzheimer's Disease, Agitation
Interventions: Not listed
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 65 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Healthy Adult, Flushing
Interventions: Genetic Test Results Return, Alcohol Flushing Education; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psychomotor Agitation, Critical Illness
Interventions: Weighted-blanket, Attention Control: Standard Blanket and Usual Comfort Measures; Other
Lead sponsor: Anmed Health; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Anderson, South Carolina

Conditions: Epilepsy, Functional Neurological Disorder, Mild Cognitive Impairment, Dementia, Parkinson Disease, Concussion, Brain, Brain Tumor, Healthy
Interventions: Acute Exercise; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease
Interventions: lecozotan SR (SRA-333); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more

Conditions: Older Adults With Elevated Dementia Risk
Interventions: Mindfulness-based walking, Walking-only; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 60 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Alzheimer Disease
Interventions: Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 37
States / cities: Phoenix, Arizona • Costa Mesa, California • Fresno, California + 28 more

Conditions: Cognitive Dysfunction, Dementia
Interventions: ToolboxDetect; Other
Lead sponsor: Northwestern University; Other
Eligibility: 65 Years and older
Enrollment: 35,403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease
Interventions: CPC-201; Drug
Lead sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc; Industry
Eligibility: 50 Years to 79 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Alzheimer Disease
Interventions: NP001, Placebo; Drug
Lead sponsor: Beau Nakamoto; Other
Eligibility: 55 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Alzheimer Disease, Caregiver Burden, Healthy Aging, Dysphagia
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alzheimer Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alzheimer's Disease
Interventions: Acetaminophen, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 65 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Dementia or a Related Disorder, Mental Health Diagnoses, Symptoms of Agitation or Aggression
Interventions: Montessori Approaches to Person-Centered Care (MAP-VA); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: Primary Progressive Aphasia, Frontotemporal Dementia
Interventions: Monthly Check-in Session; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: Not listed
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease
Interventions: lorazepam, placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Alzheimer Disease
Interventions: LX1001; Biological
Lead sponsor: Lexeo Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Orlando, Florida • Durham, North Carolina

Conditions: Primary Progressive Aphasia
Interventions: Communication Bridge™, Evidence-Based Impairment Focused; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Minocycline; Drug
Lead sponsor: Huntington Medical Research Institutes; Other
Eligibility: 55 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Alzheimer's Disease (AD)
Interventions: [18F]T807; Drug
Lead sponsor: Molecular NeuroImaging; Other
Eligibility: 20 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Dementia
Interventions: Experimental: Intervention 1 (AB): Engagement in Motion-Based Activities (Wii & Magic Table), Experimental: Intervention 2 (BA): Engagement in Motion-Based Activities (Magic Table BA); Other
Lead sponsor: Midwestern University; Other
Eligibility: 21 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Downers Grove, Illinois

Conditions: Alzheimers Disease
Interventions: No Intervention; Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: Not listed
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: Alzheimer Disease
Interventions: Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care; Drug · Combination Product
Lead sponsor: Emory University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Albany, Georgia • Atlanta, Georgia • Augusta, Georgia + 4 more

Search by objective public record fields.

Oral Hygiene in Assisted Living

The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease

ALDH2 Genetic Testing in East Asian Community

Weighted Blankets for Agitation in Adults in the Intensive Care Unit

EXercise-induced PhysioLogical Adaptations In Neurological Disorders

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

Mindful Walking Neural Correlates of Executive Function in SC Older Adults at Risk of Dementias

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

ToolBox Detect: Low Cost Detection of Cognitive Decline in Primary Care Settings

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Swallowing Impairments in Adults With and Without Alzheimer's Disease

Blood Biomarker of Alzheimer's Disease (AD)

Behavioral Expressions in Alzheimer's Disease

Effectiveness and Implementation of Montessori Approaches in Person-Centered Care Within VA

Communication Bridge Speech Therapy Research Study

The Impact of Lorazepam on Cognition in APOE e4 Carriers

Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease

Communication Bridge 3 Study

Minocycline in Patients With Alzheimer's Disease

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

Increasing Engagement and Positive Emotional Behavior of Older Adults With Mild-Moderate Dementia With the Use of Motion-Based Technology and Meaningful Activities

A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry